Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
Am Heart J. 2020 Oct;228:47-56. doi: 10.1016/j.ahj.2020.07.011. Epub 2020 Jul 17.
Am Heart J. 2020.
PMID: 32798787
Free article.
Clinical Trial.